Pacira BioSciences Inc. Revenue 2009–2025
Pacira BioSciences Inc. annual/quarterly revenue history and growth rate from 2009 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Pacira BioSciences Inc. revenue for the quarter ending March 31, 2026 was 177.4 M, a 5.00% increase year-over-year.
- Pacira BioSciences Inc. revenue for the twelve months ending March 31, 2026 was 706.9 M, a 4.32% increase year-over-year.
- Pacira BioSciences Inc. annual revenue for 2025 was 726.4 M, a 3.63% increase from 2024.
- Pacira BioSciences Inc. annual revenue for 2024 was 701.0 M, a 3.85% increase from 2023.
- Pacira BioSciences Inc. annual revenue for 2023 was 675.0 M, a 1.22% increase from 2022.
- Pacira BioSciences Inc. annual revenue for 2022 was 666.8 M.
Pacira BioSciences Inc. (PCRX) — Frequently Asked Questions
Pacira BioSciences Inc. (PCRX) is a publicly traded US company. It has a market capitalization of $1.05B. In fiscal 2025 it reported revenue of $726M and net income of $7M. Explore PCRX's stock price, financial statements, earnings history, margins and key ratios below.
What is Pacira BioSciences Inc.'s market cap?
Pacira BioSciences Inc. (PCRX) has a market capitalization of $1.05B.
What is the PCRX stock price?
PCRX trades at $23.42 (+0.90% on the day).
How much revenue does Pacira BioSciences Inc. make?
Pacira BioSciences Inc. reported revenue of $726M in fiscal 2025.
Is PCRX profitable?
In fiscal 2025, Pacira BioSciences Inc. reported net income of $7M.